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Introduction: Despite an increasing number of prostate cancer survivors in Japan, the 
current delivery of prostate cancer survivorship care is insufficient and lacks a 
multi-disciplinary approach. We conducted a study to characterize prostate cancer 
survivorship care in Japan, examine the Japanese workforce available to deliver 
survivorship care, introduce a conceptual framework for survivorship, and identify 
opportunities to improve Japanese survivorship care. 
Methods: We systematically searched PubMed for prostate cancer survivorship care 
studies, including those from Japan. We also searched the internet for prostate cancer 
guidelines relevant to survivorship care. 
Results: We found 392 articles, of which 71 were relevant, read in detail and reported here. 
In Japan, survivorship care is mostly provided by urologists. Primary care as a specialty 
does not exist in Japan, and there are no independent nurse practitioners or physician 
assistants to assist with survivorship care. Japanese quality of life studies characterize the 
long-term effects of prostate cancer treatment, but routine use of patient-reported outcomes 
is not common in Japan. In the US, in light of a growing comprehensive awareness of 
challenges facing survivors and their providers, the American Cancer Society prostate 
cancer survivorship care guidelines serve as a tool for optimizing the management of 
long-term treatment effects and coordination of care. 
Conclusions: In order to deliver high-quality survivorship care in Japan, urologists need to 
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guideline for prostate cancer survivorship care in Japan appears warranted. 
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With over 98,000 incident prostate cancer cases in 2015 and nearly 180,000 
Japanese men alive with the diagnosis of prostate cancer, the public health burden of this 
disease in Japan is significant.(1, 2)
According to the National Coalition for Cancer Survivorship, cancer survivors include 
individuals diagnosed with cancer from the time of diagnosis and for the balance of life. 
 This burden is expected to increase due to uptake of 
Western dietary patterns, prostate cancer screening, an aging Japanese population, and 
increasing effectiveness of prostate cancer treatments. With most Japanese men living with 
rather than dying from prostate cancer, focusing on opportunities to improve their quality of 
life (QOL) through better survivorship care is increasingly essential. 
(3) 
Survivorship typically refers to the phase of care following primary treatment. It has broad 
economic and long-term well-being implications for cancer patients and the health care 
system in general. The 4 essential components of survivorship care highlighted in a 
dedicated Institute of Medicine (IOM) report include cancer prevention, surveillance, 
intervention and care coordination.(4) Although most Japanese men with prostate cancer 
have favorable cancer-specific survival, prostate cancer treatment is often associated with 
lasting functional, medical, QOL, and psychosocial detriments. Prostate cancer survivorship 
issues are associated with the type of treatment (e.g., active surveillance, surgery, radiation, 
androgen deprivation therapy, chemotherapy), stage of disease, baseline function, 
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surgically with radical prostatectomy may experience persistent urinary incontinence and 
erectile dysfunction.(5, 6) Radiation therapy may cause sexual dysfunction, irritative urinary 
symptoms, and bowel symptoms due to rectal toxicity.(7-9) Androgen deprivation therapy is 
associated with a range of adverse effects including increased fracture risk,(10, 11) metabolic 
syndrome,(12) cardiovascular events,(13, 14) and anemia.(15) Involving partners and caregivers 
in survivorship care efforts is also important as they often deal with the implications of the 
disease and its treatment as part of their relationship.(16-19)
 In response to this need in the United States, the American Cancer Society (ACS) 
developed the prostate cancer survivorship care guidelines.
 In general, multi-disciplinary 
survivorship care efforts are needed to ensure the impacts of these treatment-related side 
effects on prostate cancer survivor QOL are addressed and minimized.  
(20) These novel disease-specific 
guidelines, endorsed by the American Society of Clinical Oncology (ASCO),(21) emphasize a 
multi-disciplinary approach to survivorship care including experts in mental health, sexual 
health, and physical therapy, along with primary care clinicians, urologists, and medical and 
radiation oncologists, to address treatment-related side effects.(22, 23) The focus on primary 
care clinicians is critical, at least in the US, given their role in the health care of prostate 
cancer survivors after prostate cancer treatment. While there are approximately three million 
prostate cancer survivors in the US, nearly 17 times more than in Japan, both countries 
demonstrate a significant need for survivorship care guidance to optimize the QOL and care 
for men with prostate cancer.(23, 24)
Although guidelines for prostate cancer screening and treatment exist in Japan, their 
scope of recommendations for survivorship is limited. Therefore, we first sought to 
summarize the current status of prostate cancer survivorship care in Japan through a 
narrative literature review. Next, we examined provider workforce differences, including the 
availability of primary care clinicians, nurse practitioners, and physician assistants in the US 
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conceptual model for survivorship care, describe a survivorship care plan to assist with 
longitudinal Japanese prostate cancer care coordination, and offer recommendations to 
improve Japanese prostate cancer survivorship care.  
Methods 
Narrative review 
For our narrative review, we searched PubMed for prostate cancer survivorship care 
studies through September 2015. Our search terms included: prostate cancer, survivorship 
care, quality of life, and Japan. However, only 5 articles were identified using these search 
terms. We then broadened our criteria to include prostate cancer, survivorship care, and 
quality of life without specificity for Japanese studies. Next, we included studies involving 
Japanese patients, as well as supportive interventions directed at improving prostate 
cancer-specific QOL outcomes. Using this approach, we identified 392 articles, of which 71 
were deemed relevant by the study team, read in detail and reported here. In addition, we 
conducted internet searches of relevant urologic and cancer websites for prostate cancer 
guidelines for survivorship care including those for the ACS (27), ASCO (28), and the 
Japanese Urological Association (JUA). (29)  
Prostate cancer survivorship care workforce in Japan and the US  
Because prostate cancer survivorship care is inherently multi-disciplinary, we also 
searched workforce sources for relevant data (e.g., number of urologists). We identified the 
population of both countries using the United Nations website.(25) We searched the Ministry 
of Health, Labor, and Welfare of Japan website to identify the number of physicians by major 
professional activity.(26) For the corresponding US data, we used the 2012 Physician 
Specialty Data Book published by Association of American Medical Colleges.(27) The number 
of nurses in Japan and the US were reported from the Japanese Nurse Association 
website (28) and the Health Resources and Services Administration Bureau of Health 
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tallied from the National Commission on Certification of Physician Assistants website.(30)
Current state of knowledge about Japanese prostate cancer survivorship care and 
quality of life among Japanese prostate cancer survivors. 
  
Several studies described QOL among Japanese men treated for prostate 
cancer.(31) However, most QOL studies were done in the US (47%), followed by the UK (8%), 
Canada (8%) and Japan (6%).(32) Therefore, most information about treatment outcomes, 
particularly for QOL, is based on the experience of well-educated white men and may not be 
as relevant for the Japanese population.(20) This is important, because prostate cancer 
survivors of different races may have different outcomes and needs when it comes to cancer 
control, expectations, general, urinary, bowel, and sexual QOL.(33-35) For example, Namiki et 
al. reported that Japanese men with localized prostate cancer were more likely than 
American men to report poor sexual desire and function at baseline.(36) As the cultural 
context for this difference is not fully understood and the measure used, the Expanded 
Prostate Cancer Index Composite (EPIC), while translated into Japanese, has not been 
utilized efficiently for Japanese prostate cancer survivors, it is not easy for Japanese 
urologists to know how to proactively address erectile dysfunction or other sexual health 
issues. Interestingly, a nationwide survey of breast cancer surgeons in Japan found that the 
discussion of sexuality issues was similarly limited in clinical encounters.(37) It is clear that 
there is a need for further research on how best to support Japanese survivors and their 
partners both before and after prostate cancer treatment in a culturally relevant manner.(38) 
One opportunity would be in the routine use of QOL assessment to guide clinical care. A 
validation study of EPIC (39) for routine QOL assessment of Japanese survivors could begin 
to direct care for treatment-related side-effects of prostate cancer treatment in survivorship. 
Implementing QOL assessment in clinical practice has been shown to not only increase 
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patient-physician communication during the consultation; it also helps address these 
concerns in a timely manner. (40-42)
Psychosocial issues facing Japanese prostate cancer survivors 
  
The impact of prostate cancer and its treatment on the psychosocial, including 
sexual, well-being of individuals and couples cannot be overstated. (43, 44) Prostate cancer 
survivors make difficult decisions about which treatment to pursue and once treated, (45, 46) 
must learn to manage the psychological hardship of a cancer diagnosis, post-treatment 
complications (e.g., erectile dysfunction, incontinence), and even anticipated death. (47-49) 
However, the volume of Japanese research in this area remains sparse, and the 
psychological effect of prostate cancer on Japanese patients remains under studied.(50)
We did find three papers that reported the psychological outcome related to prostate 
cancer treatment in Japan. Namiki et al. assessed 340 Japanese men who had been treated 
for localized prostate cancer and found subgroups with high psychological distress. Fifteen 
percent of patients reached a high degree of anxiety. Nearly half (46%) reported a high 
degree of depression.
  
(51) Men who experienced higher psychological distress had worse 
urinary and bowel symptoms. Namiki et al. also reported the impact of bother with urinary 
and bowel dysfunction on social activities among men in Japan and the United States 
following radical prostatectomy or brachytherapy for localized prostate cancer.(52) They 
found that the bother associated with both dysfunctions after surgery or brachytherapy for 
prostate cancer has a greater impact on social function in American men than in Japanese 
men. In another study, Taoka et al. examined Japanese localized prostate cancer patients 
treated with radical prostatectomy, brachytherapy, and external radiation therapy.(53) Using 
validated anxiety and general health scales, they found anxiety was associated with the 
mental health component summary of SF-8 indicating the interplay between psychological 
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Depression and anxiety are not rare among prostate cancer survivors. Data from a 
meta-analysis showed clinically relevant depression to be present in 17%, 15%, and 18% of 
men before, during, and after treatment for prostate cancer, respectively. Similarly, clinically 
relevant anxiety was present in 27%, 15%, and 18% of men before, during, and after 
treatment, respectively.(54) During androgen deprivation therapy for advanced stage prostate 
cancer, another study found one-quarter of patients might develop psychiatric illness, 
defined as a composite of depression, dementia, anxiety, insomnia, and psychosis.(55) 
Notably, suicidal intent in prostate cancer survivors is also associated with both physical and 
psychological dysfunction.(56)
Japanese urologists manage prostate cancer patients regardless of cancer stage, 
including those with advanced disease where one in four could develop clinically significant 
psychological morbidity. Despite extensive experience dealing with medical complications of 
prostate cancer treatment, urologists are often not proficient in managing problems such as 
social isolation, depression, job loss, and financial difficulties facing prostate cancer patients. 
Better understanding the psychological issues facing prostate cancer survivors creates 
opportunities for urologists to inquire and potentially address these issues, and/or refer 
patients to appropriate medical and supportive resources. 
  
Workforce limitations in Japan and the need for multidisciplinary team care in 
prostate cancer survivorship 
 Given the extent of collateral issues facing prostate cancer survivors, urologists 
often need the support of multi-disciplinary partners to provide optimal survivorship care. In 
other words, high-quality survivorship care requires urologists, in addition to pelvic floor 
physical therapists for continence rehabilitation, psychologists, sexual and marital 
counselors, nurse practitioners, physician assistants, peer-group support, dieticians and 
exercise physiologists. However, unlike in the US, generalist primary care clinicians are less 
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exist in Japan, and urologists, rather than oncologists, administer chemotherapy for 
advanced disease. This is quite different from the US where post-acute care for prostate 
cancer survivors is often delivered by primary care clinicians and advanced disease care is 
often shared with medical oncology.(57)
Although nurse practitioners are growing as a discipline in Japan, they are regarded 
as assistants for physicians and do not take independent roles in clinical practice. In addition, 
physician assistants as a discipline do not exist in Japan. These mid-level providers play 
important roles in cancer survivorship care in the US. They may staff cancer survivor clinics 
during and beyond prostate cancer treatment. In addition, they are often able to spend more 
time (e.g., 30-40 minutes) with patients and assist with treatment-related symptom 
management such as erectile dysfunction and urinary incontinence.
 Broadening medical care teams in Japan to include 
providers other than urologists could provide some relief to these specialists and allow for 
more focused application of medical expertise in the care of prostate cancer survivors.   
(58, 59)
Other specialists who may assist in supporting prostate cancer survivor QOL are 
currently not available in Japan’s delivery system for survivorship care. These include pelvic 
floor rehabilitation physical therapists who help manage urinary incontinence, and sexual 
health and cancer-related mental health experts who can help manage the impact of sexual 
symptoms on relationships and distress, respectively. Their presence would clearly benefit 
survivors’ abilities to alleviate treatment-related long-term symptom burdens. For example, 
recent data from Dieperink and colleagues demonstrate the value of multi-disciplinary team 
interventions among prostate cancer survivors.
  
(60) Men treated with radiation and androgen 
deprivation therapy were randomly assigned to a multi-disciplinary counseling program by 
nurses and physical therapists or usual care. The nurse counseling included psychological 
support and identified disease-specific problems for the survivor and their spouse. Physical 
therapists helped improve pelvic floor muscle function and general physical activity. At 
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improved in the intervention versus control groups. The availability of a multi-disciplinary 
program for surgical patients that included nurse practitioners, a sexual health therapist and 
physical therapists improved patients’ outcomes and satisfaction with care. (42)
Conceptual model for prostate cancer survivorship care and care planning
 While comprehensive prostate cancer survivorship care includes addressing 
cancer-specific issues (e.g., PSA surveillance), it also needs to address general health 
concerns and areas of functional, QOL, and psychosocial impairment. For example, most 
men with prostate cancer die of conditions that are modifiable through lifestyle changes (e.g. 
cardiovascular and respiratory diseases) or screening (e.g. other cancer).
 Thus, 
multi-disciplinary programs have the potential to improve survivors’ QOL.  
(61, 62) As a result, 
care for general and preventive health issues are of similar importance to care for the index 
cancer. In fact, primary care clinicians are often more effective than other specialists in 
altering survivors’ attitudes and behavior, because they are more familiar with behavioral 
counseling.(63)
 A robust approach to conceptualizing prostate cancer survivorship care is to link 
short and long-term care as shown in Figure 1a.
 In the US, family physicians who follow patients in the long term are 
specialists ideally suited to promote healthy lifestyles for prostate cancer survivors. Currently, 
this specialty is not yet recognized or available in Japan though the collaboration between 
specialists and primary care clinicians can foster quality prostate cancer survivorship care. 
(4)
The US Institute of Medicine and American College of Surgeons Commission on 
Cancer has recognized that in order to provide complex services in a seamless manner, 
linkage between services is needed. It has recommended the creation of survivorship care 
plans to fulfill this function. 
 However, emerging appreciation of the 
complex problems facing prostate cancer survivors transitioning into long-term survivorship 
care is currently not reflected in the availability of services and relevant specialists in the 
Japanese model, and several areas likely need to be expanded as illustrated in Figure 1b. 
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engage patients and other providers in disease management, and support comprehensive 
long-term care. A best practice use of the care plan means that every cancer patient be 
given a record of all care received and important disease characteristics upon discharge 
from cancer treatment, including recommended treatment of recurrences and side effects of 
treatment to share with healthcare providers in survivorship (Supporting Data 1). As a result, 
this survivorship care planning has the potential to both improve the quality of cancer 
survivorship care as well as address anticipated problems with care coordination across 
providers.(64, 65)
Challenges and potential solutions in Japanese prostate cancer survivorship care 
  
We found several challenges to providing more comprehensive, multi-disciplinary 
prostate cancer survivorship care in Japan. First, there are limited general practitioners or 
Family Medicine specialists to assist urologists in addressing general health issues for 
survivors. Most internal medicine physicians in Japan tend to focus on specialty diseases 
rather than on general wellness. However, the Japanese Medical Specialty Board plans to 
rearrange the primary boards to include a general practice/Family Medicine specialty among 
the new 19 primary boards.(66) This effort will also increase the number of family physicians. 
Second, there are no independent nurse practitioners in Japan to provide survivorship care 
support as outlined above. However, there is a Certified Nurse Specialist system in Japan 
that could have increasing roles in survivorship care. These nurses provide meticulous care 
for patients and families dealing with complicated health care challenges as in cancer 
survivorship. They do have specialty designations such as Cancer Nursing and Psychiatric 
Mental Health Nursing. At this time they only represent 0.1% of all nurses in Japan indicating 
more are needed. In addition, unlike their US counterparts, they cannot prescribe medication 
nor staff independent survivorship clinics, but could be trained to do so. While there are 
dedicated survivorship clinics in the US, they tend to reside at major cancer centers and their 
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according to World Health Statistics, Japan has some of the greatest longevity in the world, 
highlighting the long-term care needed for cancer survivors.(67) One of the reasons for this 
longevity involves a traditional lifestyle and dietary habits. Japanese tend to eat a diet rich 
with fish and plant foods and low in refined carbohydrates and animal fat. This appears to 
have been quite effective for decreasing lifestyle-related disease including the incidence of 
prostate cancer.(68) This is supported by the Multiethnic Cohort Study in which first- and 
second-generation Japanese migrants to Hawaii were found to have higher prostate cancer 
incidence compared to native Japanese.(68) Recent obesity, physical inactivity, and 
unfavorable dietary habits (high calorie, high fat, and low vegetable) trends in Japan could 
trigger an increase the risk of prostate cancer creating even more survivors.(69, 70)
Prostate cancer survivorship resources to help guide care in Japan 
 Last, there 
are several clinical guidelines for diagnosis and treatment of prostate cancer available to 
Japanese urologists. These include JUA guideline, a Japanese version of The National 
Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines, and a Japanese 
version of the Physician Data Query (PDQ). However, we found no clinical guidelines 
specific to prostate cancer survivorship care in Japan. This lack of Japanese-specific 
guidance necessitates efforts to translate other survivorship resources as discussed below.  
Given the multiple treatment options and numerous adverse effects associated with 
prostate cancer treatment, addressing late and long-term effects has the potential to 
improve prostate cancer survivor QOL.(71) We found the number of post-treatment resources 
for cancer survivors in Japan (e.g. health promotion) to be limited compared to the US 
indicating opportunities to enhance these resources.(72, 73) Therefore, we highlight several 
resources for Japanese providers in Table 3 including internet sites for treatment and 
survivorship care guidelines, decision support, and healthy living recommendations for 
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While there is a JUA clinical guideline for prostate cancer, it does not cover many of 
the issues facing long-term prostate cancer survivors highlighted in Table 4. The recently 
published ACS Prostate Cancer Survivorship Guidelines can help fill this gap.(20) This 
comprehensive disease-specific guideline was endorsed by the American Society of Clinical 
Oncology, (21) and targeted to post-treatment prostate cancer survivors and their providers. 
The guidelines addresses (1) health promotion, (2) surveillance for recurrence, (3) screening 
and early detection of second primary cancers, (4) assessment and management of physical 
and psychosocial long-term and late effects, and (5) care coordination and practice 
implications.(20)
The ACS guideline goes beyond typical urology-related issues (e.g., management of 
incontinence and erectile dysfunction, disease-specific QOL) to address other critical health 
promotion and psychosocial issues discussed above (e.g., dietary advice, physical activity, 
nutrition, sexual health, anxiety and depression). For example, there are recommendations 
for 1) use of a post-treatment patient-reported measure of side effect burden (e.g., EPIC for 
Clinical Practice (EPIC-CP)) 
  
(74) to facilitate longitudinal self-management and medical 
management efforts, and 2) at least annual assessment of late and long-term QOL effects 
(e.g., Sexual Health Inventory for Men) including the psychosocial effects of the cancer 
diagnosis.(75) Another rich resource offering self, medical, and surgical management for 
prostate cancer treatment and side effects comes from the Michigan Cancer Consortium 
recommendations for prostate cancer survivorship care (Supporting Data 2). Although 
primary care clinicians rarely follow prostate cancer survivors in Japan, these guidelines can 
assist urologists and radiation oncologists following prostate cancer survivors, as well as 
other specialists engaged in treatment such as physiotherapists and psychologists. They 
also offer prostate cancer survivors insight into the opportunities to engage in 
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 Although self-management, diet and other health promotion approaches for cancer 
survivors are not well-recognized in Japan, lifestyle modification and behavioral change can 
improve both physical and psychological well-being. Jones and Demark-Wahnefried 
conducted an extensive literature review regarding health promotion for cancer survivors.(76) 
They highlighted weight management, nutrition and diet, exercise, smoking cessation, 
limited alcohol use, sunscreen use, complementary and alternative therapies, osteoporosis 
prevention, and immunizations. Although controversies exist regarding the intensity, length, 
and timing of interventions as well as patients’ preferred delivery channel, many 
interventions aimed at lifestyle modifications enhanced the survivors’ QOL, and some 
interventions, especially physical activity, increased survival.(76-80) Furthermore, Yang et al. 
recently offered insight on how diet may help improve survivorship for the patients 
diagnosed with prostate cancer in the US. Men eating a mostly Western diet (those in the 
highest quartile of the Western dietary pattern) had two-and-a-half times higher risk of 
prostate cancer-related death—and a 67% increased risk of death from any cause—than 
those ate mostly a “prudent” diet (higher consumption of vegetables, fruits, fish, legumes, 
and whole grains).(81)
Summary 
 Taken together, evidence suggests lifestyle modification and 
behavioral change recommendations for prostate cancer survivors can improve quality and 
quantity of life. 
While comprehensive prostate cancer survivorship care includes addressing 
cancer-specific issues (e.g., PSA surveillance), it also needs to address general health 
concerns and areas of functional, QOL and psychosocial impairment. In order to provide 
high-quality prostate cancer survivorship care, Japanese urologists need to cooperate with a 
variety of multi-disciplinary providers including pelvic floor physical therapists for continence 
rehabilitation, psychologists, sexual and marital counselors, peer support, dieticians and 
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US health care system, efforts to enrich the current approach to long-term survivorship care 
can improve disease-specific QOL as well as psychosocial and sexual well-being of 
individuals and couples. In addition, there is increasing QOL research in Japanese men with 
localized prostate cancer. However, Japanese urologists should also strive to incorporate 
QOL assessment into routine clinical care and use discussion of outcomes to improve 
patient-physician communication and address unmet need. Prostate cancer survivorship 
care guidelines and self-management materials can be especially helpful for providers and 
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Figure Legends 
Figure1. Conceptual models for prostate cancer survivorship care.(4)
1a- An ideal conceptual model of follow up care and cancer survivorship. (Hewitt M et al. The 
national Academics press 2006.) 1b- A real practice model of cancer survivorship care in 
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Table 1: Physical and Psychosocial Long-Term and Late Effects (19)  






• Urinary incontinence (stress) 
• Urinary symptoms (urgency, 
frequency, nocturia, dribbling) 
• Urethral stricture formation (scarring 
at the urethra) 
Sexual dysfunction 
• ED 
• Lack of ejaculation 
• Orgasm changes (without erection, 
associated with incontinence) 






• Urinary incontinence 
• Urinary symptoms (dysuria, 
urgency, frequency, nocturia, 
dribbling) 
• Hematuria 
• Urethral stricture 
Sexual dysfunction 
• Progressive ED 
• Decreased semen volume 
Bowel dysfunction 
• Fecal urgency, frequency, 
incontinence 
• Blood in stool 
• Rectal inflammation, pain 
Urinary dysfunction 
• Urethral stricture 
• Hematuria due to small blood vessel 
changes 
Sexual dysfunction 
• ED can be delayed in onset 6 to 36 
mo after therapy 
Bowel dysfunction 
• Rectal bleeding secondary to 
thinning/small blood vessel changes 
of anterior rectal wall mucosa 




• Loss of libido 
• ED 
Other 
• Hot flushes/sweats 
• Weight gain, abdominal obesity 
• Change in body image 
• Excessive emotional reactions and 
frequent mood changes 
• Depression 
• Osteoporosis, fractures 
• Metabolic syndrome 
• Cardiovascular disease (possible 
increased risk of myocardial 
infarction) 
• Diabetes; decreased sensitivity to 
insulin and oral glycemic agents 
• Increased cholesterol 
• Increased fat mass and decreased 
















This article is protected by copyright. All rights reserved 
• Fatigue/decreased activity 
• Gynecomastia 
• Anemia 
• Body hair loss 
• Dry eyes 
• Venous thromboembolism 
• Vertigo 
• Cognitive dysfunction 




watchful waiting) † 
• Stress, anxiety, worry 
• Risks associated with repeat biopsy 
(active surveillance), PSAs and DREs 
• Symptoms associated with disease 
progression 
• Disease progression 
  
  
GENERAL PSYCHOSOCIAL LONG-TERM AND LATE EFFECTS 
• Depression, depressive symptoms 
• Distress (multifactorial unpleasant experience of psychological, social, and/or spiritual nature) 
• Worry, anxiety 
• Fear of recurrence 
• Pain-related concerns 
• End-of-life concerns: death and dying 
• Changes in sexual function and/or desire 
• Challenges with body image (secondary to surgery, hormonal therapy) 
• Challenges with self-image 
• Relationship and other social role difficulties 
• Return to work concerns and financial challenges 
 
ED, indicates erectile dysfunction; PSA, prostate-specific antigen; DRE, digital rectal examination. 
† According to the National Cancer Institute Dictionary of Cancer Terms, active surveillance indicates a treatment plan that involves 
closely watching a patient's condition but not giving treatment unless there are changes in test results that show the condition is 
getting worse. Active surveillance may be used to avoid or delay the need for treatments such as radiation therapy or surgery, which 
can cause side effects or other problems. During active surveillance, certain exams and tests are done on a regular schedule. It may 
be used in the treatment of certain types of cancer, such as prostate cancer. It is a type of expectant management. Watchful waiting 
indicates closely watching a patient's condition but not giving treatment unless symptoms appear or change. Watchful waiting is 
sometimes used in conditions that progress slowly. It is also used when the risks of treatment are greater than the possible benefits. 
During watchful waiting, patients may be given certain tests and exams. Watchful waiting is sometimes used in prostate cancer. It is 
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Table 2. Comparison of health care providers involved in prostate cancer survivorship care in 
US and Japan. 
 
Provider characteristics US Japan 
Number of Doctors a 798,398 288,850 
Density per 1000 population 2.5 2.3 
Internal Medicine (% in doctors) b 108,817 (13.6%) 61,177 (21.2%) 
Family Medicine/General Practice (% in doctors) 106,391 (13.3%) - 
Urology (% in doctors) 9,824 (1.2%) 6,754 (2.3%) 
Hematology and Oncology c 12,724 (1.6%) - 
Medical oncology d - 1,050 (0.3%)  
Number of Nurses e 1,427,497 1,470,421 
Density per 1000 population 4.4 11.5 
Number of nurse practitioner (% in nurses) 158,348 (11.1%) - 
Certified Nurse Specialist (% in nurses) - 1,466 (0.1%) 
Number of physician assistant f 95,108 - 
Density per 1000 population 0.3 - 
 
a US (2010), Japan (2012) 
b This number does not include internal medicine subspecialists 
c Hematology and oncology are separated in Japan. 
d The number is from the report from Japanese society of medical oncology (September 
2015). Medical oncology is subspecialty board in Japan. 
(http://www.jsmo.or.jp/authorize/lists.html) 
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Table 3: Prostate cancer resources for health care providers and patients in US and Japan  
 
US JP 
Treatment guidelines for urologists 




Japan Urological Association, Clinical guideline for 
prostate cancer, 
http://minds.jcqhc.or.jp/n/medical_user_main.php 




Japan Society of Clinical Oncology, Clinical 
practice guideline for prostate cancer, 
http://www.jsco-cpg.jp/guideline/26.html 
Up To Date for health professionals, 
http://www.uptodate.com/ 
NCCN guideline, Japanese translation, 
http://www.tri-kobe.org/nccn/guideline/urological/ 
 
PDQ Prostate Cancer Treatment- for health 
professionals, Japanese translation, 
http://cancerinfo.tri-kobe.org/ 
Treatment decision guidance for patients 
NCCN guideline for patients, 
http://www.nccn.org/patients/ 
Public service (Information for prostate cancer), 
http://ganjoho.jp/public/cancer/prostate/treatment_
option.html 
American Cancer Society Fact sheet for 
professionals, http://www.cancer.org/ 
Private network (Senyu-Net; Prostate cancer 
support network), http://pros-can.net/index.html 
Up to date for patient information, 
http://www.uptodate.com/ 
Private network (Senyu-Net), 
http://pros-can.net/01/01-1.html 
Cancer patient education network, 
http://www.cancerpatienteducation.org/  
Prostate cancer survivorship care guidelines for health providers 
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Post-treatment resources for cancer survivors including healthy living issues 
NCCN Clinical Practice Guidelines in Oncology, 
Survivorship: www.NCCN.org 
NPO project, http://kibou.jp/survivorship.html 
ASCO Guidelines for Survivorship Care, 
http://www.asco.org/asco-releases-first-three-guid
elines-cancer-survivorship-care 
Pharmaceutical company sponsored service, 
http://www.gan-guide.jp/ 
Up to date for patient information, 
http://www.uptodate.com/ 
Private network (Senyu-Net; Prostate cancer 
support network), http://pros-can.net/index.html 
 




Private Network related to work opportunities, 
http://workingsurvivors.org/ 
Post-treatment resources for cancer survivors and partners regarding sexual health 
Michigan Cancer Consortium, 
http://prostatecancerdecision.org/index.htm 
None 
American Association of Sexuality Educators, 
Counselors and Therapists, 
https://www.aasect.org/ 
 
Society for Sex Therapy and Research, 
http://www.sstar.org/  
Sexual Medicine Society of North America, 
http://www.smsna.org/V1/index.php  
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Table 4 Comparison between American Cancer Society (ACS) prostate cancer survivorship guidelines and the Japan Urological 























ACS prostate cancer 
survivorship guidelines 
● ● ● ● ● ● ● ● ● 










*1 Only mention risk 
*2 Recommendation of penile rehabilitation using PDE5 
ADT: Androgen deprivation therapy 
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